VivoSeq
Other

MDD

1

Pipeline Programs↗

3

Active Trials↗

8

Companies Involved↗

MDD is an early-stage landscape with 1 program across 8 companies. The most active players are Algernon Pharmaceuticals, Small Pharma Ltd, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Algernon Pharmaceuticals

1 program

Phase 2S

Small Pharma Ltd

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalLundbeck logo

Lundbeck

0 programs

PreclinicalA

Avalo Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

N,N-Dimethyltryptamine

Algernon Pharmaceuticals

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

17

clinical trials

Completed12 · 71%
Recruiting2 · 12%
Unknown status2 · 12%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Study of ALTO-300 in MDD
Recruiting·—·Phase 2·NCT05922878·321 enrolled
Randomized, Double-Blind, Placebo-Controlled Phase IIb Trial of Inhaled N,N-Dimethyltryptamine (DMT) for Major Depressive Disorder
Recruiting·UUniversidade Federal do Rio Grande do Norte·Phase 2·NCT07562191·140 enrolled
Neurocognitive Effects of FMT in MDD Patients With and Without IBS
Active, not recruiting·—·Phase 2/3·NCT05174273·133 enrolled
MDD POC Study GSK372475 Subjects Depressive Disease
Completed·GSK logoGSK·Phase 2·NCT00420641·492 enrolled
SPL026 With or Without SSRIs in Participants With MDD
Completed·SSmall Pharma Ltd·Phase 1·NCT05553691·18 enrolled
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
Completed·Pfizer logoPfizer·Phase 2·NCT00163059·30 enrolled
PD, PK, and Safety of ALTO-203 in Patients With MDD
Completed·—·Phase 2·NCT06391593·69 enrolled
Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
Completed·Lundbeck logoLundbeck·Phase 4·NCT02332954·226 enrolled
A Study of Intermittent Doses of CERC-301 in MDD
Completed·AAvalo Therapeutics, Inc.·Phase 2·NCT02459236·115 enrolled
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Completed·RRelmada Therapeutics, Inc.·Phase 2·NCT03051256·62 enrolled
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
Completed·Bayer logoBayer·Phase 3·NCT00824187·187 enrolled
Effect of Self-administered tDCS in Patients With MDD
Completed·—·Phase 4·NCT04543123·58 enrolled
SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
Completed·SSmall Pharma Ltd·Phase 1/2·NCT04673383·66 enrolled
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
Completed·Pfizer logoPfizer·Phase 3·NCT00445679·807 enrolled
ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD
Completed·AAlkermes, Inc.·Phase 1/2·NCT01381107·32 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)